Skip to main content

Xynomic Pharmaceutical Holdings Inc. (XYNO)

Jun 17, 2021 - XYNO was delisted (reason: merged with Xu-Nuo Pharma)
2.22 0.00 (0.00%)
Jun 16, 2021 9:30 AM EDT - Market closed
Market Cap102.73M
Revenue (ttm)n/a
Net Income (ttm)-26.80M
Shares Out32.28M
EPS (ttm)-4.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume0
Open2.22
Previous Close2.22
Day's Range2.22 - 2.22
52-Week Range0.20 - 3.79
Beta-3.89
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About XYNO

Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma ...

IndustryBiotechnology
Founded2016
Employees27
Stock ExchangeOTCMKTS
Ticker SymbolXYNO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.